MedTrace Logo

Relationship Between Eye Pressure and Ganglion Cell Function in Eyes Receiving Latanoprost Versus Placebo

NCT01042665 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 82

Last updated 2014-03-28

No results posted yet for this study

Summary

The purpose of this investigation is to evaluate the relationship between IOP fluctuation, RGC dysfunction, and optic nerve and retinal nerve fiber layer (RNFL) thickness changes in patients with glaucoma and ocular hypertension receiving latanoprost 0.005% versus placebo.

Conditions

Interventions

DRUG

latanoprost 0.005%

Active comparator

DRUG

Placebo

Placebo comparator

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Miami

    lead OTHER

Principal Investigators

  • David S Greenfield, MD · University of Miami Bascom Palmer Eye Institute

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01042665 on ClinicalTrials.gov